View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Jan. 11 (HealthDay News) -- Treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists for at least 20 weeks leads to weight loss in obese or overweight patients with or without type 2 diabetes mellitus, according to a study published online Jan. 11 in BMJ.
Tina Vilsbøll, M.D., of the University of Copenhagen in Denmark, and colleagues conducted a systematic review and meta-analysis. They included 21 randomized, controlled trials with 6,411 adults with a body mass index of ≥25 kg/m², with or without type 2 diabetes mellitus. The participants received either exenatide twice daily, exenatide once weekly, or liraglutide once daily at clinically relevant doses for at least 20 weeks.
The researchers found the GLP-1R agonist groups achieved greater weight loss than the control groups (weighted mean difference, −2.9 kg; 95 percent confidence interval, −3.6 to −2.2). There was evidence of intertrial heterogeneity but, in regression analyses, no evidence of bias or small study effects was found. Beneficial effects of GLP-1R agonists were seen for systolic and diastolic blood pressure, plasma concentrations of cholesterol, and glycemic control, but there were no significant effects seen for plasma concentrations of liver enzymes.
"The present review provides evidence that treatment with GLP-1R agonists leads to weight loss in overweight or obese patients with or without type 2 diabetes mellitus," the authors write.
Editorial (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top